Special precautions when using mitapivat-Pyrukynd

Mitapivat-Pyrukynd, a pyruvate kinase (PK) activator under the trade name Pyrukynd, provides a new oral treatment option for adult patients with PK deficiency, which can improve chronic hemolytic anemia and improve quality of life. However, extra attention needs to be paid to safety and potential risks during use, especially during drug interruptions or dosage adjustments. Reports from overseas drug regulatory agencies show that sudden interruption of mitava therapy may lead to an acute hemolytic reaction, and patients may experience symptoms such as worsening anemia, jaundice, darker urine, dizziness, fatigue, and even difficulty breathing. Therefore, it is clinically recommended to avoid sudden discontinuation of the drug, but to gradually reduce the dose under the guidance of a doctor, while closely monitoring hematological indicators to prevent acute hemolytic events.

In addition, mitapival may also cause liver cell damage at high doses or when used in patients with nonPK deficiency. Especially in the first six months of treatment, liver function needs to be closely monitored, including regular measurement of alanine aminotransferase (ALT) and other indicators. If elevated liver enzymes are found to be more than five times the upper limit of normal or are accompanied by jaundice, treatment should be discontinued immediately and further evaluation should be performed. Overseas guidelines recommend a comprehensive liver function test before starting mitava treatment and monthly rechecks in the early stages of treatment to detect potential risks of liver damage in a timely manner. Through these monitoring measures, the occurrence of adverse reactions can be minimized while ensuring the efficacy.

Safe use of metapival also involves patient education and self-monitoring. Patients should understand the risks of discontinuing medication, pay attention to signs of changes in liver function, and promptly report any abnormal symptoms to their doctor. For doctors, the key to ensuring the long-term efficacy and safety ofPyrukynd is to rationally formulate the dosage plan, adjust the dosage according to the patient's weight and hematological status, and conduct regular follow-up visits.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd